The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment – Blood Cancer Journal

This study shows that production of neutralizing antibodies against COVID are low in patients with myeloma, and impaired especially in patients receiving anti CD38 antibodies or belantamab.

Read the full article here

Related Articles